Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5528442 | 0.86 | NR1H4 (0.43) | SMN1; SMN2RAB9A | |
| SCHEMBL5528655 | 0.86 | ALDH1A1 (0.53) | MAPTGPR52SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5527532 | 0.86 | SMN1; SMN2 (0.48) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5522180 | 0.85 | HCAR2 (0.46) | HCAR2SMN1; SMN2RAB9AALDH1A1CHRM4 | |
| SCHEMBL5522721 | 0.85 | TRPM8 (0.53) | MAPTSMN1; SMN2NPC1RAB9ATRPM8 | |
| SCHEMBL5524260 | 0.85 | PPARA (0.40) | MAPTL3MBTL1SMN1; SMN2RAB9ATRPM8 | |
| SCHEMBL5520198 | 0.84 | RXFP1 (0.45) | MAPTGPR52RAB9AALDH1A1 | |
| SCHEMBL5522334 | 0.84 | SMN1; SMN2 (0.39) | GPR52SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5527609 | 0.84 | CACNA1G (0.38) | SMN1; SMN2NPC1RAB9AALDH1A1CHRM4 | |
| SCHEMBL5524844 | 0.84 | CHRM4 (0.39) | SMN1; SMN2ALDH1A1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108565-A1 | PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108565-A1 | PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS | POLI, POLB, POLA1 | HCAR2 878/4885MAPT 2190/4885L3MBTL1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.